1.
Sesquiterpene lactones: Adverse health effects and toxicity mechanisms
by Amorim, M. Helena R
Critical reviews in toxicology, 2013-08, Vol.43 (7), p.559-579
2.
Systematic review: the role of the gut microbiota in chemotherapy‐ or radiation‐induced gastrointestinal mucositis – current evidence and potential clinical applications
by Touchefeu, Y.
Alimentary pharmacology & therapeutics, 2014-09, Vol.40 (5), p.409-421
3.
Renal Transporters in Drug Development
by MORRISSEY, Kari M
Annual review of pharmacology and toxicology, 2013, Vol.53 (1), p.503-529
4.
Drug Transporters in Drug Efficacy and Toxicity
by DEGORTER, M. K
Annual review of pharmacology and toxicology, 2012, Vol.52 (1), p.249-273
5.
Rapid translocation of nanoparticles from the lung airspaces to the body
by Bawendi, Moungi G
Nature biotechnology, 2010-12, Vol.28 (12), p.1300-1303
6.
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis
by SHUBBER, Zara
AIDS (London), 2013, Vol.27 (9), p.1403-1412
7.
Review article: herbal hepatotoxicity – an update on traditional Chinese medicine preparations
by Teschke, R.
Alimentary pharmacology & therapeutics, 2014-07, Vol.40 (1), p.32-50
8.
New insights into the mechanism of action of amphetamines
by FLECKENSTEIN, Annette E
Annual review of pharmacology and toxicology, 2007, Vol.47 (1), p.681-698
9.
Hepatic and Intestinal Drug Transporters: prediction of Pharmacokinetic Effects Caused by Drug-Drug Interactions and Genetic Polymorphisms
by YOSHIDA, Kenta
Annual review of pharmacology and toxicology, 2013, Vol.53 (1), p.581-612
10.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
by Fellay, Jacques
The Lancet (British edition), 2001, Vol.358 (9290), p.1322-1327
11.
The COXIB Experience : A Look in the Rearview Mirror
by MARNETT, Lawrence J
Annual review of pharmacology and toxicology, 2009, Vol.49 (1), p.265-290
12.
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
by Armstrong, M. J.
Alimentary pharmacology & therapeutics, 2013-01, Vol.37 (2), p.234-242
13.
Drug hypersensitivity: Pharmacogenetics and clinical syndromes
by Phillips, Elizabeth J., MD
Journal of allergy and clinical immunology, 2011, Vol.127 (3), p.S60-S66
14.
Diagnosis, management and prevention of drug-induced liver injury
by Verma, S
Gut, 2009-11, Vol.58 (11), p.1555-1564
15.
Olmesartan‐associated enteropathy: results of a national survey
by Marthey, L.
Alimentary pharmacology & therapeutics, 2014-11, Vol.40 (9), p.1103-1109
16.
Chemotherapy-induced peripheral neuropathy
by QUASTHOFF, Stefan
Journal of neurology, 2002, Vol.249 (1), p.9-17
17.
Systems Pharmacology to Predict Drug Toxicity: Integration Across Levels of Biological Organization
by BAI, Jane P. F
Annual review of pharmacology and toxicology, 2013, Vol.53 (1), p.451-473
18.
Triclosan: A critical review of the experimental data and development of margins of safety for consumer products
by Rodricks, Joseph V
Critical reviews in toxicology, 2010-05, Vol.40 (5), p.422-484
19.
The role of metabolic activation in drug-induced hepatotoxicity
by PARK, B. Kevin
Annual review of pharmacology and toxicology, 2005, Vol.45 (1), p.177-202
20.
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity
by Sánchez-González, Penélope D
Critical reviews in toxicology, 2011-11, Vol.41 (10), p.803-821
